July 2022 EGRP Cancer Epidemiology News

EGRP Cancer Epidemiology News


Call for Nominations: Candidate Variants Sought for Functional Assessment

In recent decades, many genomic regions associated with the risk of developing cancer have been identified. A critical next step is to understand how these genomic variants impact disease risk. This field of study, functional genomics, brings together basic cancer biologists and genetic epidemiologists to gain insight into disease mechanisms, to understand variants of unknown significance, and to explore these mechanisms for cancer prevention and treatment strategies. Through functional genomics, existing data and evidence is leveraged to design thoughtful experiments to characterize the biological and clinical consequences of harboring risk variants. Although the tools for functional genomics exist, challenges remain in bridging the gap between association and function and harnessing the efficiencies of high throughput assays and systematic evidence reviews.

In recognition of these challenges, the NIH Office of Research Infrastructure Programs launched the Pilot Centers for Precision Disease Modeling Initiative. This program funds multiple functional genomic centers that have created systematic pipelines for assessing human genomic variants linked to diseases and harnessing cost-effective, high-throughput testing in models (e.g. mouse, rat, C. elegans, zebrafish, Drosophila, Xenopus embryos, and human cell lines) for functional assessment. Although these programs have existed in some form for many years, cancer genetic epidemiologists have had limited interaction with these resources.

In May 2022, these Precision Centers for Disease Modeling were highlighted during the Sequencing Strategies for Population and Cancer Epidemiology Studies (SeqSPACE) webinar series hosted by NCI’s Epidemiology and Genomics Research Program. A recording of the session is available for viewing. In this session, the three funded Centers provided an overview of their capabilities, described their pipelines for assessing nominated variants for functional follow-up efforts, and described exemplar projects.

The time is right for cancer genetic epidemiologists to leverage these resources for functional genomics to provide a clearer understanding of disease mechanisms. If you have rare, common, coding or noncoding candidate variants for functional assessment, please consider nominating them through one or more of these Centers.

Nomination forms can be found here:

If you would like more information, please contact Dr. Danielle Daee.

Funding Opportunities

  • RFA-DA-23-011, Registry of Medical Cannabis Use and Health Outcomes (UM1, Clinical Trial Optional)*
  • RFA-ES-22-003, Research Coordinating Center to Support Climate Change and Health Community of Practice (U24, Clinical Trial Not Allowed)
  • PAR-22-114, Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)
    Note: Program staff will host a pre-application webinarExternal Web Site Policy on Friday, August 5, 2022, from 2:00-3:00 pm ET.
  • PAR-22-164, Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01, Clinical Trial Optional)
  • Notice of Intent to Publish a Funding Opportunity Announcement for Environmental influences on Child Health Outcomes (ECHO)
    • NOT-OD-22-169, Measurement Core (U24, Clinical Trial Not Allowed)
    • NOT-OD-22-170, Laboratory Core (U24, Clinical Trial Not Allowed)
    • NOT-OD-22-172, Cohort Coordinating Center (U2C, Clinical Trial Not Allowed)
    • NOT-OD-22-173, Data Analysis Center (U24, Clinical Trial Not Allowed)
  • Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Environmental influences on Child Health Outcomes (ECHO)
    • NOT-OD-22-171, Pregnancy Cohort Study Sites (UG3/UH3, Clinical Trial Not Allowed)
    • NOT-OD-22-174, Pregnancy and Pediatric Cohort Study Sites (UG3/UH3, Clinical Trial Not Allowed)
    • NOT-OD-22-175, Cohort Study Sites for Pediatric Follow Up (UG3/UH3, Clinical Trial Not Allowed)
  • NOT-ES-22-006, Notice of Special Interest (NOSI): Climate Change and Health
  • NOT-TW-22-003, NOSI: Climate Change and Health Administrative Supplements
  • NOT-OD-22-135, NOSI: Stimulating Research to Understand and Address Hunger, Food and Nutrition Insecurity
  • NOT-CA-22-085, NOSI: Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer
  • NOT-CA-22-083, NOSI: Technologies and Informatics Tools for Cancer Metabolomics
    Note: There will be a pre-application webinar on July 25, 2022. See NOT-CA-22-083 for details and to register.
  • NOT-CA-22-092, Notice to Extend Expiration Date for PAR-20-276: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01, Clinical Trial Not Allowed)
  • NOT-CA-22-093, Notice to Extend Expiration Date for PAR-20-277: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21, Clinical Trial Not Allowed)
  • DoD Congressionally Directed Medical Research Program Funding OpportunitiesExternal Web Site Policy

*NCI is not participating.

Requests for Information

Research Resources

Job & Training Opportunities

NIH & NCI News

Blog Posts

Stay Connected

Subscribe for Updates

Subscribe
You can subscribe and unsubscribe at any time by entering your email address and selecting your preferences on the page that follows.

Subscribe to the E-Newsletter

Need Help?

EGRP staff can answer questions on grant funding, policies, and research resources. If you do not know who to contact we will do our best to connect you with someone who can help you.

Email Us
(240) 276-6730